finance

Fitbit
Health Tech

As European Commission decision looms, Google faces continued scrutiny over Fitbit deal

By Erin Brodwin

Benjamins
Health Tech

Proving predictions wrong, health tech funding keeps climbing

By Juliet Isselbacher

Digital pill illustration part deux
Health Tech

Smart pill maker Proteus files for bankruptcy, reveals it has held acquisition talks with Otsuka

By Rebecca Robbins

Doctor consulting patient
First Opinion

Fee for service is a terrible way to pay for health care. Try a subscription model instead

By Vivian S. Lee

Rollercoaster
Biotech

‘An extremely volatile time’: New report underscores the recent roller coaster of the biotech market 

By Kate Sheridan

Money
Biotech

Medical device startup raises almost $44M to advance a less-invasive treatment for fluid in the brain

By Jonathan Saltzman — Boston Globe

AstraZeneca building
Pharmalot

Why would AstraZeneca want to buy Gilead? Some analysts say it’s not entirely clear

By Ed Silverman

Virus Outbreak Rural Hospitals
First Opinion

Covid-19 is changing the game for health care companies and investors

By Eric M. Stone

AstraZeneca building
Biotech

In a first for RNA-modifying drugs, AstraZeneca partners with startup Accent Therapeutics

By Kate Sheridan

Franklin faces
Health Tech

Despite economic downturn, big names in health tech are drawing in significant funding

By Erin Brodwin

Pharmaceutical production
Pharmalot

After years of manufacturing problems, Akorn files for bankruptcy protection

By Ed Silverman

Surprise bills concept
First Opinion

Three traps for the unwary in HHS’ provider relief fund

By Mark Hedberg, James Pinna, and Sean O’Connell

Something ventured illo
Something Ventured

Dyne Therapeutics and three other startups got venture funding a year ago. Will it be enough to get them through Covid-19?

By Kate Sheridan

Cambridge: AbbVie
Pharmalot

FTC approves AbbVie’s $63 billion deal for Allergan amid scornful dissent

By Ed Silverman

calculating financial budget biopharma companies
First Opinion

How biopharma companies can keep ‘feeding the beast’ in the time of coronavirus

By Gregg Beloff

Pharmalot

Covid-19 is forcing smaller biotechs to cut spending and change financing plans

By Ed Silverman

ws trading floor monitor
Health Tech

A gulf emerges in health tech: While some companies surge, others lay off their workers

By Rebecca Robbins and Erin Brodwin

one hundred dollars bills
Biotech

The coronavirus pandemic could shrink some biotech startup valuations 

By Kate Sheridan

Video conferencing
Biotech

On a 180-person video chat, biotech executives share the best ways do business amid the coronavirus

By Kate Sheridan

Pharmalot

Dozens of financial firms want pharma to place Covid-19 patients over profits

By Ed Silverman

revenues folder
Biotech

Biotech venture capital had a record-breaking quarter, but isn’t out of the woods yet

By Kate Sheridan

aerial view Lombard st
Health Tech

A rare investment mechanism is helping to fund some health tech companies’ coronavirus projects 

By Kate Sheridan

SF empty streets
Health Tech

Coronavirus-related layoffs hit health tech startups

By Rebecca Robbins and Erin Brodwin

startup desk
Health Tech

Digital health startups scored a critical cash infusion at the start of this year

By Erin Brodwin

money stack
Biotech

Big biotech venture funds raise billions despite coronavirus fears

By Matthew Herper and Kate Sheridan

doc entering er dept.
Health

Amid coronavirus, private equity-backed company slashes benefits for emergency room doctors

By Lev Facher

Video Chat

STAT Plus video chat: Biotech in uncharted territory

By Adam Feuerstein and Matthew Herper

NYSE - 3/16
First Opinion

The economic rationale for strong action now against Covid-19

By Mireille Jacobson and Tom Chang

Stock Market Down
Biotech

As the market craters, Keros Therapeutics files for an IPO

By Kate Sheridan

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy